Bristol Myers Squibb

BMS, Avidity add another link to cardiovascular partnership with $100M expansion
BMS, Avidity add another link to cardiovascular partnership with $100M expansion
Fierce Biotech
Bristol Myers Squibb
Avidity Biosciences
R&D
cardiovascular disease
Flag link:
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
Flag link:
BMS gets US approval for ROS1 lung cancer drug Augtyro
BMS gets US approval for ROS1 lung cancer drug Augtyro
Pharmaphorum
Bristol Myers Squibb
Augtyro
Turning Point Therapeutics
lung cancer
FDA
Flag link:
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Motley Fool
Merck
Bristol Myers Squibb
antibody-drug conjugate
Flag link:
Bristol Myers pays $100M for a different kind of ADC
Bristol Myers pays $100M for a different kind of ADC
BioPharma Dive
Bristol Myers Squibb
antibody-drug conjugate
bone cancer
blood cancer
Orum Therapeutics
Flag link:
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Flag link:
Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow
Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow
Zacks.com
Bristol Myers Squibb
earnings
Flag link:
Bristol Myers says it needs another year to hit target for new drugs
Bristol Myers says it needs another year to hit target for new drugs
Reuters
Bristol Myers Squibb
Reblozyl
Sotyktu
Zeposia
Flag link:
BMS buys Asian rights to key growth drug Camzyos
BMS buys Asian rights to key growth drug Camzyos
Pharmaphorum
Bristol Myers Squibb
Asia
Camzyos
obstructive hypertrophic cardiomyopathy
Flag link:
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Flag link:
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
Flag link:
BMS, Halozyme score with subcutaneous version of Opdivo
BMS, Halozyme score with subcutaneous version of Opdivo
Fierce Pharma
Bristol Myers Squibb
Halozyme
Opdivo
clinical trials
Flag link:
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Fierce Pharma
Bristol Myers Squibb
Opdivo
melanoma
FDA
Flag link:
Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity
Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity
Fierce Pharma
Bristol Myers Squibb
Zeposia
Pfizer
Velsipity
etrasimod
ulcerative colitis
FDA
Flag link:
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
CP Wire/Businesswire
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
cancer
Krazati
Flag link:
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
Flag link:
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Drugs.com
Paradigm Health
Bristol Myers Squibb
clinical trials
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
AstraZeneca, BMS Reluctantly Agree to Medicare Drug Price Negotiation Program
AstraZeneca, BMS Reluctantly Agree to Medicare Drug Price Negotiation Program
BioSpace
AstraZeneca
Bristol Myers Squibb
drug pricing
Inflation Reduction Act
Medicare
Flag link:
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Flag link:

Pages